PT  - JOURNAL ARTICLE
AU  - SHINYA YAMAMOTO
AU  - TAKASHI CHISHIMA
AU  - YUKAKO SHIBATA
AU  - SHIORI INOUE
AU  - FUMI HARADA
AU  - HIDEKI TAKEUCHI
AU  - AKIMITSU YAMADA
AU  - KAZUTAKA NARUI
AU  - ITARU ENDO
TI  - Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer
AID  - 10.21873/invivo.12774
DP  - 2022 Mar 01
TA  - In Vivo
PG  - 859--864
VI  - 36
IP  - 2
4099  - http://iv.iiarjournals.org/content/36/2/859.short
4100  - http://iv.iiarjournals.org/content/36/2/859.full
SO  - In Vivo2022 Mar 01; 36
AB  - Background/Aim: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. Patients and Methods: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. Results: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. Conclusion: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer.